Healthcare
MDxHealth S.A.(MDXH)
Live Price
Offline$0.4975
-8.38% today
1Y Change
-77.69%
Window
Jun 25, 2025 → Jun 22, 2026
- Market Cap
- $110.00M
- Revenue Growth
- +19.8%
- EPS Growth
- +14.1%
- Dividend Yield
- 0.0%
Coverage: 248 bars · Jun 25, 2025 → Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
MDxHealth S.A. (MDXH) is a Healthcare stock with a market cap of $110.00M and listed on NASDAQ. The stock last traded around $0.50 and down 77.7% across the available one-year price window (Jun 25, 2025 → Jun 22, 2026). Baseline metrics include revenue growth of +19.8%, EPS growth of +14.1%, a dividend yield of 0.0%. What stands out right now is revenue +19.8%, EPS +14.1%, free cash flow +44.1% with operating margin -14.3% and ROIC -14.5%. Valuation is more restrained than many high-expectation growth names at price/sales 1.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines MDXH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+19.8% vs +7.6% peer median
Operating Margin
Below sector median
-14.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +19.8% and EPS at +14.1%, with operating margin around -14.3%.
Benchmark Edge
MDXH vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MDXH
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MDXH Max Drawdown
-90.05%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MDXH and SPY.
Company Overview
MDxHealth S.A.
NASDAQ Capital Market
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
- Leadership
- Michael K. McGarrity
- IPO Date
- Nov 4, 2021
- Employees
- 312
- Street Address
- CAP Business Center
- Mailing
- Herstal, 4040
- Region
- Herstal, BE
- Reporting Currency
- USD
- Investor Line
- 32 4 257 70 21
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- 1.0
- Price/Book
- —
Growth
- Revenue
- +19.8%
- EPS
- +14.1%
- Free Cash Flow
- +44.1%
Profitability
- Gross Margin
- 59.7%
- Operating Margin
- -14.3%
- Net Margin
- -31.1%
- ROE
- 516.6%
- ROIC
- -14.5%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 1.08
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.